📉 $NVO — Novo Nordisk shares fall more than 6% before the market opens.
📰 On the news front, Novo Nordisk raised its full-year outlook. The maximum possible decline in sales and profits this year is now expected to reach 6%, compared with prior guidance that pointed to a drop of up to 12%.
💊 Wegovy tablet sales in the second quarter were 3.22 billion Danish kroner, slightly below expectations of 3.27 billion.
Wegovy is one of the leading modern products in the obesity treatment drug market, with big hopes pinned on its future success.
🏭 The company also plans to expand its production capacity by 2030, aiming to serve a number of obese patients using oral GLP-1 drugs—up to 10 times the current level
📰 On the news front, Novo Nordisk raised its full-year outlook. The maximum possible decline in sales and profits this year is now expected to reach 6%, compared with prior guidance that pointed to a drop of up to 12%.
💊 Wegovy tablet sales in the second quarter were 3.22 billion Danish kroner, slightly below expectations of 3.27 billion.
Wegovy is one of the leading modern products in the obesity treatment drug market, with big hopes pinned on its future success.
🏭 The company also plans to expand its production capacity by 2030, aiming to serve a number of obese patients using oral GLP-1 drugs—up to 10 times the current level